Replies to post #33611 on Ariad Pharmaceuticals Inc fka ARIA

[ariadndndough]

i am having troulbe copying page 18 in tabel format. but please go there and look PONA is such a superior drug and just needs time to play out.


Table 02: Effect of Ponatinib, Imatinib, Nilotinib, and Dasatinib on Viability of Ba/F3 Cells Dependent on Native or 14 Mutant Variants of BCR-ABL
Ba/F3 Cell Viability Assay
IC50 (nM)
BCR-ABL
Ponatinib1
Imatinib2
Nilotinib2
Dasatinib2
Native
0.5
260
13
0.8
M244V
2.2
2000
38
1.3
G250E
4.1
1350
48
1.8
Q252H
2.2
1325
70
3.4
Y253F
2.8
3475
125
1.4
Y253H
6.2
>6400
450
1.3
E255K
14
5200
200
5.6
E255V
36
>6400
430
11
T315A
1.6
971
61
125
T315I
11
>6400
>2000
>200
F317L
1.1
1050
50
7.4
F317V
10
350
nd
53
M351T
1.5
880
15
1.1
F359V
10
1825
175
2.2
H396P
1.1
850
41
0.6
Parental
1713
>6400
>2000
>200
1: Report OHSU-001
2: O'Hare T. et al (2005) Cancer Res. 65: 4500-4505. O'Hare T. et al (2007) Blood. 110: 2242-2249.
nd=not determined

[bellweather1]

MORE HOMEWORK???

Seriously, an excellent resource and documentation of Ponatinib's depth and range of potential...

[iandy]

taken from last nights 100 page pona paper. i suggest all read it.

I got to page 46, skipping the stuff I though was not important.
Kindly refrain from posting documents that long or do some abridging first.

:-)